Maia Biotechnology, INC

MAIA Biotechnology shareholders re-elected Class I directors and ratified the appointment of Grant Thornton LLP as auditors.

MAIA Biotechnology, Inc. has announced the termination of its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, effective seven business days after May 14, 2026.

MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 trial targeting advanced non-small cell lung cancer.

MAIA Biotechnology announced a $33 million capital raise expected to fully fund its Phase 3 trial for ateganosine, a novel telomere-targeting therapy for non-small cell lung cancer.

MAIA Biotechnology announced overall survival exceeding two years for eight non-small cell lung cancer patients in its Phase 2 THIO-101 clinical trial, significantly surpassing expected survival rates.

MAIA Biotechnology, Inc. announced the presentation of positive clinical data for its THIO-101 trial at the European Lung Cancer Congress 2026, highlighting sustained response in NSCLC patients.

MAIA Biotechnology, Inc. reports substantial progress in its Phase 2 and Phase 3 oncology trials, bolstered by significant capital raises, while continuing to navigate the inherent financial challenges of drug development.

MAIA Biotechnology, Inc. reported its first quarter 2026 financial results, highlighting increased operating expenses and significant cash inflow from financing activities, while advancing its lead oncology drug candidate, ateganosine.

MAIA Biotechnology reported increased operating expenses and a net loss for Q3 2025, while advancing its lead cancer drug ateganosine in clinical trials and adopting a new digital asset treasury plan.

MAIA Biotechnology reports progress in its lead lung cancer drug trials and secures new funding, despite ongoing financial challenges and a going concern warning.

MAIA Biotechnology announces its Q1 2025 financial results, showcasing advancements in its cancer immunotherapy programs and strategic collaborations.

MAIA Biotechnology's Q3 2024 report details financial results, clinical trial progress, and ongoing efforts to develop cancer therapies.

MAIA Biotechnology reports significant clinical progress for its lead cancer drug ateganosine, initiates Phase 3 trials, and strengthens its financial position with recent capital raises, despite ongoing net losses.

MAIA Biotechnology's 10-K filing highlights positive survival data from its THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) and outlines the company's financial status and future plans.

MAIA Biotechnology's 10-K filing details its securities, clinical trial progress, and intellectual property, highlighting its focus on telomere-targeting cancer therapies.

MAIA Biotechnology, Inc. reports that Director Steven M. Chaouki acquired stock options on June 30, 2026, under the company's 2021 Equity Incentive Plan.

Ramiro Guerrero, a Director at MAIA Biotechnology, Inc., acquired 26,355 stock options on June 30, 2026, under the company's 2021 Equity Incentive Plan.

MAIA Biotechnology, Inc. reports that Director Cristian Luput acquired 27,610 stock options on June 30, 2026, under the company's 2021 Equity Incentive Plan.

MAIA Biotechnology, Inc. reports that Director Stan Smith acquired stock options representing 32,003 shares of common stock.

MAIA Biotechnology, Inc. reports that Director Jean-Manasse Theagene was granted stock options for 26,355 shares.

MAIA Biotechnology, Inc. reports a significant stock purchase by CEO Vlad Vitoc, increasing his direct beneficial ownership.

MAIA Biotechnology announces its 2026 Annual Meeting of Stockholders to be held virtually on May 21, 2026, with key proposals including director elections and auditor ratification.

MAIA Biotechnology, Inc. has filed a definitive proxy statement with the SEC.

MAIA Biotechnology is holding its annual shareholder meeting virtually on May 22, 2025, to vote on director elections, auditor ratification, and an increase in authorized common stock.

MAIA Biotechnology announces its 2024 Annual Meeting of Shareholders to be held virtually on May 24, 2024, to vote on director elections and the ratification of the company's independent auditor.

MAIA Biotechnology, Inc.'s CEO and Chairman, Vlad Vitoc, increased his beneficial ownership in the company to 9.66% through recent open market purchases and equity awards.

Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 4.9% of MAIA Biotechnology, Inc. common stock.

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 7.1% of MAIA Biotechnology, Inc.'s common stock as of March 31, 2026.

FGMK Business Holdings, LLC and FGMK, LLC have jointly disclosed a 9.99% beneficial ownership stake in MAIA Biotechnology, Inc., primarily through a combination of open market purchases, private placements, and warrant exercises.

Sergei M. Gryaznov, an insider at MAIA BIOTECHNOLOGY, INC., has filed an amended Schedule 13G reporting a beneficial ownership of 4.08% of the company's common stock as of December 31, 2023.